Genetic Vulnerabilities Identified in Residual TNBC After Neoadjuvant Chemo

As for future research, "efforts to determine whether lesions present in the residual disease mirror those in the recurrence and whether they are selected during neoadjuvant treatment are under way," he concluded.

The research was funded by the Susan G. Komen for the Cure Foundation, the National Institutes of Health, and the Lee Jeans/Entertainment Industry Foundation Translational Breast Cancer Research Program. Dr. Balko disclosed no relevant conflicts of interest. Dr. Arteaga disclosed he is a consultant/adviser for Roche, Monogram Biosciences, AstraZeneca, GlaxoSmithKline, and Genentech, and that he receives research grants from Amgen, AstraZeneca, and Exelixis.